Karyopharm Therapeutics Inc Working Capital to Net Assets Ratio
Karyopharm Therapeutics Inc working capital to net assets ratio. Karyopharm Therapeutics Inc (KPTI) has a Working Capital to Net Assets ratio of 8.4% as of June 2026. Working capital of $-27.86 Million (current assets of $106.38 Million minus current liabilities of $134.23 Million) is measured against net assets of $-330.17 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Karyopharm Therapeutics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Karyopharm Therapeutics Inc (2011–2025)
Working capital to net assets ratio of Karyopharm Therapeutics Inc from 2011 to 2025. This chart shows how Karyopharm Therapeutics Inc's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 8.4%, reflecting working capital of $-27.86 Million against net assets of $-330.17 Million USD. See KPTI days of operational coverage to measure how many days the company can operate on defensive assets alone.
Karyopharm Therapeutics Inc Working Capital to Net Assets Ratio by Year (2011–2025)
Karyopharm Therapeutics Inc working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Karyopharm Therapeutics Inc from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Karyopharm Therapeutics Inc (KPTI) total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -3.8% | $11.09 Million | $-292.93 Million | $103.15 Million | $92.06 Million | ▲ +30.7 pp |
| 2024 | -34.5% | $64.23 Million | $-186.02 Million | $156.49 Million | $92.26 Million | ▲ +86.2 pp |
| 2023 | -120.7% | $164.44 Million | $-136.21 Million | $233.92 Million | $69.48 Million | ▲ +1585.9 pp |
| 2022 | -1706.6% | $284.25 Million | $-16.66 Million | $350.16 Million | $65.91 Million | ▼ -1453.2 pp |
| 2021 | -253.4% | $201.89 Million | $-79.67 Million | $275.61 Million | $73.72 Million | ▼ -825.6 pp |
| 2020 | 572.2% | $289.24 Million | $50.55 Million | $289.54 Million | $297.00K | ▲ +115.5 pp |
| 2019 | 456.7% | $227.31 Million | $49.77 Million | $273.67 Million | $46.35 Million | ▲ +299.6 pp |
| 2018 | 157.1% | $287.71 Million | $183.17 Million | $334.61 Million | $46.90 Million | ▲ +80.6 pp |
| 2017 | 76.4% | $98.96 Million | $129.46 Million | $148.42 Million | $49.47 Million | ▲ +5.5 pp |
| 2016 | 71.0% | $115.16 Million | $162.24 Million | $131.64 Million | $16.48 Million | ▼ -10.9 pp |
| 2015 | 81.9% | $162.47 Million | $198.37 Million | $177.60 Million | $15.13 Million | ▼ -12.6 pp |
| 2014 | 94.5% | $195.45 Million | $206.79 Million | $207.75 Million | $12.30 Million | ▼ -5.3 pp |
| 2013 | 99.8% | $154.66 Million | $154.93 Million | $157.96 Million | $3.29 Million | ▲ +96.3 pp |
| 2012 | 3.5% | $-976.00K | $-27.88 Million | $954.00K | $1.93 Million | ▲ +41.0 pp |
| 2011 | -37.5% | $4.75 Million | $-12.65 Million | $6.87 Million | $2.12 Million | — |